Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

The Blunt Truth

DECEMBER 22, 2023

UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. The letter raises concerns about the potential for abuse, a lack of medical treatment potential, and trafficking by criminal gangs.

DEA 52

DEA Retail Programs Hemp 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Background.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.”

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. The governor also signed Senate Bill 1700 to protect the privacy of doctors recommending low-THC marijuana and their patients.

Law 126

Law Marijuana Patients Treatment 126

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 11, 2021

Cannabis cannot be lawfully prescribed by physicians; physicians can only “recommend” its use to patients based on individual state laws that identify who qualifies as a patient for its use. Cannabis faces an overall lack of access to financial institutions as well as IRC 280E, and ketamine certainly does not.

Law 104

Law Compliance Compliance DEA 104

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.”

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions.

Law 105

Law Research and Development Therapy DEA 105

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 5520), and the Veterans Equal Access Act (H.R. However, it is clear that there is momentum to give veterans access to cannabis. Yes, it has.

Law 62

Law Chronic Pain Conditions Legislation 62

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. See Deborah Brauser, FDA Permits Psilocybin to Be Tested for Refractory Depression, MEDSCAPE (Oct.

Law 105

Law Therapy Clinical Trials Research and Development 105

CannaMD

MAY 6, 2020

However, given rapidly evolving – and often complicated – laws surrounding medical marijuana, many patients feel overwhelmed. In practice, the chances of feds or the DEA sitting at the border waiting to catch someone – that’s just not happening. Visiting Qualifying Patients. Planning a vacation should be fun.

Hash 103

Hash Legalization Marijuana Concentrates 103

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

SpeedWeed

MAY 15, 2021

For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. For 88% of people who receive this treatment, we can expect to see a treatment response. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

SpeedWeed

JULY 22, 2021

The attorney general can also choose to waive that right and let the DEA review the petition instead. . Each day cannabis remains overly scheduled, patients and researchers across the United States continue to lose access to life-saving therapies and data.”. And Joyce and Young’s cannabis activism doesn’t end there.

DEA 52

DEA Therapy Cannabis Patients 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. Commercial Operations. Traditionally Regulated Medical Practice.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

MAY 24, 2022

Defendant and respondent Oakland Cannabis Buyers’ Cooperative created a medical dispensary that would serve eligible patients. In 2011, the DEA again dismissed a petition, claiming a lack of accessible studies especially on smoked marijuana in the United States.

DEA 52

DEA History Medicine Marijuana 52

Cannabis Law Report

FEBRUARY 28, 2022

Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.

Research and Development 117

Research and Development Education Agriculture Patients 117

Canna Law Blog

NOVEMBER 16, 2021

The enforcement role moves from DEA to ATF. When it comes to enforcing federal cannabis regulations, the Drug Enforcement Administration (“DEA”) is out and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (“ATF”) is in (in addition to TTB as the primary overseer). . International law and treaties.

DEA 87

DEA Business Banking Food 87

Cannabis Law Report

APRIL 13, 2022

market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.” Clinics will also offer family and couples counselling, as well as in-person and virtual group therapy for expanded access to innovative treatments.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JULY 30, 2019

The informed patients, cannabis industry employees, and clinicians find it equally difficult to keep updated on Florida’s latest medical marijuana program news and changes. . In light of all this state cannabis information overload, what are some of the reasons a patient ultimately chooses a qualified personal cannabis physician? .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

The Cannigma

MAY 6, 2021

Other than serving as a lighter version of delta-9-THC, delta-8 has also been researched as a potential treatment for a number of medical conditions and symptoms such as vomiting and nausea, glaucoma, pain, and inflammation. The vast majority of scientific knowledge is based on animal studies, however.

THC 145

THC Cannabinoids Concentrates Hemp 145

The Cannigma

SEPTEMBER 12, 2021

This contradiction, combined with a problematic regulatory framework that limits access to THC products in many states, has created a booming market for d-8 and d-10. Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only.

THC 98

THC Research and Development Cannabinoids CBD 98

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. The governor of Alabama signed a recreational bill into law in 2021, but patients will likely not have access to retail products until 2022.

Recreational 52

Recreational Data Cannabis DEA 52

Cannabis Law Report

SEPTEMBER 23, 2021

Tracking recent data from within the last year (following the publication of the DEA Interim Final Rule which added confusion to the delta-8 legality question), more than a dozen hospital or emergency room visits and hundreds of calls to poison control were reported. Delta-8 THC products should be kept out of the reach of children and pets.

THC 52

THC Concentrates Pets DEA 52

PrestoDoctor

JANUARY 14, 2020

They are responsible for giving you information about the treatment and proper use. Other states have a list of conditions that the patients must meet to get an MMJ. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Your patient status remains confidential.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

They are responsible for giving you information about the treatment and proper use. Other states have a list of conditions that the patients must meet to get an MMJ. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Your patient status remains confidential.

Marijuana 52

Marijuana Patients Conditions Programs 52

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis?

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

FEBRUARY 23, 2019

Mr O’Brien also runs the longest running dispensary in the world: The Patients Care Collective in Berkely. What made the Patients Care Collective different? “We We were patient-focused,” he said. “We We were patient-focused,” he said. The DEA was targeting those people who put their heads above the parapet.

Cultivation 40

Cultivation Patients Compliance Compliance 40

Cannabis Law Report

JULY 14, 2021

“Closing the door on broadly supported incremental reforms like the SAFE Banking Act while the Senate seeks compromise on farther-reaching bills hurts the possibilities for consensus and ignores the very real needs of small business operators who have repeatedly said that access to banking services and traditional lending is an existential issue.

Legislation 71

Legislation Banking History Access 71

The Cannigma

FEBRUARY 16, 2022

So, with that, we should get into it, but don’t forget to check out our segment with Americans for Safe Access. We always have a nice little tidbit when we’re all about advocacy and access to cannabis for all. Codi Peterson here with our regularly scheduled segment with Americans for Safe Access. How are you?

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73